UK markets open in 6 hours 15 minutes

Poxel S.A. (0RA2.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.60000.0000 (0.00%)
At close: 07:29AM GMT
Full screen
Previous close1.6000
Open5.6442
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.6000 - 1.6000
52-week range1.6000 - 1.6000
Volume78,599
Avg. volumeN/A
Market cap394,955
Beta (5Y monthly)1.33
PE ratio (TTM)N/A
EPS (TTM)-0.8300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy

    LYON, France, January 25, 2023--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced that European Commission has granted orphan drug designation (ODD) for PXL770 and PXL065 for the treatment of adrenoleukodystrophy (ALD). The decision follows a positive opinion from the Committ

  • Business Wire

    Poxel Announces Upcoming Participation at Investor Conferences

    LYON, France, January 04, 2023--POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its upcoming participation at conferences organized by Oddo BHF and Degroof Petercam to be held in January 2023.

  • Business Wire

    Poxel Announces its Financial Calendar for 2023

    LYON, France, January 03, 2023--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2023.